Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from SMS Pharmaceuticals Limited ( (IN:SMSPHARMA) ).
SMS Pharmaceuticals Limited reported its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with the statutory auditors issuing an unmodified opinion, underscoring the integrity of its financial reporting. The board also approved a statement on the use of funds raised via preferential issue, signalling continued regulatory compliance and transparency for investors.
The board recommended a final dividend of ₹0.40 per equity share for FY 2025-26, subject to shareholder approval, offering a tangible return to investors. It additionally cleared the shifting of the registered office within Hyderabad and confirmed the appointment of new cost auditors and reappointment of internal auditors for FY 2026-27, steps that fine-tune governance and operational oversight without altering the company’s core business footprint.
More about SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited is an India-based pharmaceutical company focused on manufacturing and supplying active pharmaceutical ingredients and related products. Listed on both BSE and NSE, the company operates from Hyderabad and serves domestic and international markets within the broader healthcare and life sciences sector.
Average Trading Volume: 14,680
Technical Sentiment Signal: Buy
Current Market Cap: 39.69B INR
For an in-depth examination of SMSPHARMA stock, go to TipRanks’ Overview page.